Skip to main content

On-Demand: Just in Time Release of CAR T-Cell Therapies During COVID-19

  

Webinar Overview:

Listen to Irving Ford, Head of Quality at Adaptimmune* discuss rapid microbial methods like the BACT/ALERT® and the BIOFIRE® Mycoplasma for testing short shelf-life products.

Irving has over 28 years of QA/QC experience in the pharmaceutical/biotechnology and cell and gene therapy industries. He was a significant contributor to activities supporting the commercial approval of Novartis’ CAR T product, Kymriah. He is also an active member of PDA and had served on several planning committees for various PDA conferences.

Watch Now →

Learn more about our rapid answers for in-process and release testing >

*At the time of this webinar recording, Irving Ford was the Head of Quality at Bristol Myers Squibb

(This webinar is sponsored by bioMérieux.)

Test Tubes

   

Related Resources

Cell and Gene Therapies

Cell and gene therapies are one of today’s most cutting edge-scientific approaches to treating or curing serious diseases such as cancers or genetic disorders. These innovative medicines are designed to halt a disease or reverse its progress, providing improved patient outcomes. They could help reduce or eliminate the need for treatments that need to be taken continuously. However developing and manufacturing cell and gene therapies present many challenges.
Learn More

What is CAR-T Cell Therapy?

CART-T Cell Therapy is an innovative and personalized treatment for certain types of blood cancer. Learn how this kind of treatment works and why CART-T Cell Therapy is unique.
Learn More

CAR-T Cell Therapy: For Which Indications?

CART-T Cell Therapy is currently indicated for specific types of blood cancer. Watch our short video to learn more about the different types of blood cancer and which types of patients CAR-T Cell Therapy is indicated for.
Learn More